Oncology is one of the strongest signals in Trial Watch Edition 11, with six high signal programs across GIST, CLL, multiple myeloma, B ALL, neuroendocrine carcinoma and ovarian cancer.
GSK is taking Velzatinib into Phase 3 directly against imatinib in first line GIST, challenging one of oncology’s longest standing standards. Nurix is also moving NX 5948, the first BTK degrader to reach Phase 3, against pirtobrutinib in relapsed or refractory CLL.
The category also shows platform competition expanding through BCMA bispecifics, subcutaneous blinatumomab, DLL3 targeting and FR alpha ADC development.